Strategic Blueprint’s Alexion Pharmaceuticals ALXN Stock Holding History

Strategic Blueprint’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9	Closed	-$2K	–	1443
2021 Q2	$2K	Buy	+9	New	+$1.54K	﹤0.01%	1265

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Strategic Blueprint's ALXN Position: Q3 2021 in Review

Strategic Blueprint sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9 shares — an estimated $2K sold.

Strategic Blueprint first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Strategic Blueprint reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 9 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2K.
Strategic Blueprint first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Strategic Blueprint's Alexion Pharmaceuticals position peaked at $2K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.